Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Pacira Pharmaceuticals stock

Learn how to easily invest in Pacira Pharmaceuticals stock.

Pacira Pharmaceuticals Inc is a drug manufacturers-specialty & generic business based in the US. Pacira Pharmaceuticals shares (PCRX) are listed on the NASDAQ and all prices are listed in US Dollars. Pacira Pharmaceuticals employs 697 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Pacira Pharmaceuticals

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – PCRX – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Pacira Pharmaceuticals stock price (NASDAQ: PCRX)

Use our graph to track the performance of PCRX stocks over time.

Pacira Pharmaceuticals shares at a glance

Information last updated 2022-06-24.
Latest market close$58.63
52-week range$45.05 - $82.16
50-day moving average $64.18
200-day moving average $61.97
Wall St. target price$77.73
PE ratio 68.4505
Dividend yield $0 (0%)
Earnings per share (TTM) $0.84

Buy Pacira Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 6 of 6
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
Finder Award
Stocks, ETFs, Cryptocurrency
when you sign up and deposit $100
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, or TN.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.
SoFi Invest
Stocks, ETFs, Cryptocurrency
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
Stocks, Options, ETFs, Cryptocurrency
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$125 - $625
when you open and fund an account with $25,000 - $250,000+
Axos Bank Self Directed Investing
when you open an account and deposit at least $1500.
Vanguard Personal Advisor
Stocks, Mutual funds, ETFs
Financial advice powered by relationships, not commissions.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Pacira Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Pacira Pharmaceuticals price performance over time

Historical closes compared with the close of $58.63 from 2022-06-29

1 week (2022-06-22) 8.11%
1 month (2022-05-27) -9.02%
3 months (2022-03-30) -22.52%
6 months (2021-12-30) -3.71%
1 year (2021-06-30) -3.38%
2 years (2020-06-30) 11.74%
3 years (2019-06-28) 34.81%
5 years (2017-06-29) 21.64%

Is Pacira Pharmaceuticals stock undervalued or overvalued?

Valuing Pacira Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Pacira Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Pacira Pharmaceuticals's P/E ratio

Pacira Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 68x. In other words, Pacira Pharmaceuticals shares trade at around 68x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Pacira Pharmaceuticals's EBITDA

Pacira Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $177 million.

The EBITDA is a measure of a Pacira Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.

Pacira Pharmaceuticals financials

Revenue TTM $580.5 million
Operating margin TTM 22.96%
Gross profit TTM $345.7 million
Return on assets TTM 5.24%
Return on equity TTM 5.65%
Profit margin 6.62%
Book value $15.75
Market capitalisation $2.6 billion

TTM: trailing 12 months

Pacira Pharmaceuticals share dividends

We're not expecting Pacira Pharmaceuticals to pay a dividend over the next 12 months.

Pacira Pharmaceuticals share price volatility

Over the last 12 months, Pacira Pharmaceuticals's shares have ranged in value from as little as $45.05 up to $82.16. A popular way to gauge a stock's volatility is its "beta".

PCRX.US volatility(beta: 0.89)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Pacira Pharmaceuticals's is 0.8857. This would suggest that Pacira Pharmaceuticals's shares are less volatile than average (for this exchange).

Pacira Pharmaceuticals overview

Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature only to targeted nerves. It also develops proprietary multivesicular liposome, a drug delivery technology that encapsulates drugs without altering their molecular structure. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019.

Frequently asked questions

What percentage of Pacira Pharmaceuticals is owned by insiders or institutions?
Currently 1.165% of Pacira Pharmaceuticals shares are held by insiders and 112.562% by institutions.
How many people work for Pacira Pharmaceuticals?
Latest data suggests 697 work at Pacira Pharmaceuticals.
When does the fiscal year end for Pacira Pharmaceuticals?
Pacira Pharmaceuticals's fiscal year ends in December.
Where is Pacira Pharmaceuticals based?
Pacira Pharmaceuticals's address is: 5401 West Kennedy Boulevard, Tampa, FL, United States, 33609
What is Pacira Pharmaceuticals's ISIN number?
Pacira Pharmaceuticals's international securities identification number is: US6951271005
What is Pacira Pharmaceuticals's CUSIP number?
Pacira Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 695127100

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site